广泛期小细胞肺癌一线化疗联合免疫治疗后巩固性胸部放疗:多机构病例系列
该多机构病例系列纳入2018至2021年接受一线化疗联合免疫治疗后行巩固性胸部放疗的广泛期小细胞肺癌患者20例,中位随访12个月,中位总生存期16个月,6个月总生存率94.7%、12个月总生存率77.5%,3级及以上毒性0%、2级肺炎0%、2级食管炎5%,作者认为该方案看似安全且结局与已发表的现代临床试验相当,需进一步研究确定巩固性胸部放疗的治疗效应。
要点
- 20例广泛期小细胞肺癌患者接受一线化疗联合免疫治疗后巩固性胸部放疗,中位随访12个月。
- 中位总生存期16个月,6个月总生存率94.7%,12个月总生存率77.5%。
- 3级及以上毒性0%,2级肺炎0%,2级食管炎5%。
核心结论
- 作者认为,广泛期小细胞肺癌采用一线化疗联合免疫治疗后巩固性胸部放疗看似安全,且结局与已发表的现代临床试验相当。
- 作者指出需进一步研究以确定化疗联合免疫治疗后巩固性胸部放疗的治疗效应。
研究设计与样本
- 在2家机构识别接受一线化疗联合免疫治疗后巩固性胸部放疗的广泛期小细胞肺癌患者。
- 数据集共纳入2018年至2021年治疗的20例患者,中位随访12个月。
- 评估结局包括总生存期、无进展生存期、局部无进展生存期、远处无进展生存期和毒性。
主要发现
- 该队列中位总生存期为16个月,6个月总生存率94.7%,12个月总生存率77.5%(与历史对照相当)。
- 毒性发生率低,包括3级及以上毒性0%、2级肺炎0%、2级食管炎5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需进一步研究以确定化疗联合免疫治疗后巩固性胸部放疗的治疗效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Survival for patients with extensive-stage small cell lung cancer (ES-SCLC) remains poor. Consolidative thoracic radiation therapy (cTRT) and upfront immunotherapy with chemotherapy have each incrementally improved patient outcomes, but have not yet been combined in clinical trials. We sought to characterize outcomes and toxicities after first-line chemotherapy and immunotherapy followed by cTRT. METHODS AND MATERIALS: Patients with ES-SCLC who were treated with first-line chemotherapy and immunotherapy followed by cTRT were identified at 2 institutions. Patient outcomes including overall survival (OS), progression-free survival, local progression-free survival, distant progression free-survival, and toxicity were assessed. RESULTS: Twenty patients were included in our data set treated from 2018 to 2021 with a median follow-up of 12 months. Median OS in this cohort was 16 months with 6-month OS of 94.7% and 12-month OS of 77.5% (comparable to historical controls). There were also low rates of toxicity, including 0% grade 3+ toxicity, 0% grade 2 pneumonitis, and 5% grade 2 esophagitis. CONCLUSIONS: Treatment of ES-SCLC with first-line chemoimmunotherapy followed by cTRT appears to be safe and to have outcomes comparable to published modern clinical trials. Further studies are warranted to determine the therapeutic effect of cTRT after chemoimmunotherapy.
引用
- Diamond BH, Verma N, Shukla UC, et al. Consolidative Thoracic Radiation Therapy After First-Line Chemotherapy and Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multi-Institutional Case Series. Adv Radiat Oncol. 2021. PMID: 35387416. doi:10.1016/j.adro.2021.100883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。